Full-length article|Articles in Press

Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study

Published:February 24, 2023DOI:


      Background aims

      The RELIANCE study has demonstrated the activity and safety of relmacabtagene autoleucel (relma-cel) (JW Therapeutics [Shanghai] Co, Ltd, Shanghai, China), a CD19-targeted chimeric antigen receptor T-cell product, in patients with heavily pre-treated relapsed/refractory large B-cell lymphoma (r/r LBCL). This study aimed to report the updated 2-year data of the RELIANCE study.


      The RELIANCE study (NCT04089215) was an open-label, multi-center, randomized, phase 1/2 registrational clinical trial conducted at 10 clinical sites in China. Adult patients with heavily pre-treated r/r LBCL were enrolled and received lymphodepletion chemotherapy followed by infusion of 100 × 106 or 150 × 106 relma-cel. The primary endpoint was objective response rate (ORR) at 3 months, as assessed by investigators. Secondary endpoints were duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety profiles.


      From November 2017 to January 2022, a total of 68 patients were enrolled, and 59 patients received relma-cel infusion. As of March 29, 2022, a total of 59 patients had a median follow-up of 17.9 months (range, 0.3–25.6). ORR was 77.59% (95% confidence interval [CI], 64.73–87.49) and complete response rate was 53.45% (95% CI, 39.87–66.66). Median DoR was 20.3 months (95% CI, 4.86–not reached [NR]) and median PFS was 7.0 months (95% CI, 4.76–24.15). Median OS was NR and 1-year and 2-year OS rates were 75.0% and 69.3%, respectively. Three (5.1%) patients experienced grade ≥3 cytokine release syndrome and two (3.4%) patients had grade ≥3 neurotoxicity.


      The updated data of the RELIANCE study demonstrate durable response with and manageable safety profile of relma-cel in patients with heavily pre-treated r/r LBCL.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • WHO
        WHO classification of tumours of haematopoietic and lymphoid tissue.
        4th ed. World Health Organization, Geneva2008
      1. National Comprehensive Cancer Network. B-Cell Lymphomas (version 4.2021). 2021. [accessed 20 June 2022].

        • Crump M
        • Neelapu SS
        • Farooq U
        • et al.
        Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
        Blood. 2017; 130: 1800-1808
        • Morrison VA
        • Shou Y
        • Bell JA
        • et al.
        Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
        Future Oncology (London, England). 2019; 15: 1021-1034
        • Gisselbrecht C
        • Glass B
        • Mounier N
        • et al.
        Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
        Journal of clinical Oncology. 2010; 28: 4184-4190
        • Hamadani M
        • Hari PN
        • Zhang Y
        • et al.
        Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
        Biology of Blood and Marrow Transplantation. 2014; 20: 1729-1736
        • Neelapu SS
        • Locke FL
        • Bartlett NL
        • et al.
        Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
        N Engl J Med. 2017; 377: 2531-2544
        • Locke FL
        • Ghobadi A
        • Jacobson CA
        • et al.
        Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
        Lancet Oncol. 2019; 20: 31-42
        • Abramson JS
        • Palomba ML
        • Gordon LI
        • et al.
        Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
        Lancet. 2020; 396: 839-852
        • Schuster SJ
        • Tam CS
        • Borchmann P
        • et al.
        Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
        Lancet Oncology. 2021; 22: 1403-1415
      2. European Medicines Agency. Yescarta (axicabtagene ciloleucel) Summary of Product Characteristics. 2020. [accessed 20 June 2022].

      3. Kite Joint Venture—FosunKite—gains the first CAR T-cell therapy approval in China [press release]. 2021.–fosun-kite–gains-the-first-car-t-cell-therapy-approval-in-china. [accessed 25 June 2021].

      4. United States Food and Drug Administration. YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion. 2021. [accessed 20 June 2022].

      5. United States Food and Drug Administration. BREYANZI® (lisocabtagene maraleucel) suspension for intravenous infusion. 2021. [accessed 20 June 2022].

        • Zhu J
        • Ying Z
        • Song Y
        • et al.
        Clinical response of CD19 CAR-T cells (relmacabtagene autoleucel, relma-cel) in adults with heavily-pre-treated relapsed/refractory (r/r) large B-cell lymphoma in China.
        Blood. 2020; 136: 39-40
        • Ying Z
        • Yang H
        • Guo Y
        • et al.
        Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
        Cancer Medicine. 2021; 10: 999-1011
        • Cheson BD
        • Fisher RI
        • Barrington SF
        • et al.
        Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
        J Clin Oncol. 2014; 32: 3059-3068
        • Cazzola M
        Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues.
        Blood. 2016; 127: 2361-2364
        • Cheson BD
        • Fisher RI
        • Barrington SF
        • et al.
        Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
        Journal of Clinical Oncology. 2014; 32: 3059-3068
        • National Cancer Institute (US)
        Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
        U.S. Department of Health and Human Services, Bethesda, MD2010
        • Lee DW
        • Gardner R
        • Porter DL
        • et al.
        Current concepts in the diagnosis and management of cytokine release syndrome.
        Blood. 2014; 124: 188-195
        • Neelapu SS
        • Tummala S
        • Kebriaei P
        • et al.
        Chimeric antigen receptor T-cell therapy—assessment and management of toxicities.
        Nat Rev Clin Oncol. 2018; 15: 47-62
        • Clopper CJ
        • Pearson ES
        The use of confidence or fiducial limits illustrated in the case of the binomial.
        Biometrika. 1934; 26: 404-413
        • Schuster SJ
        • Bishop MR
        • Tam CS
        • et al.
        Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.
        N Engl J Med. 2019; 380: 45-56
        • Ying Z
        • Song Y
        • Zhu J.
        Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
        Front Pharmacol. 2022; 25834113
        • Ying Z
        • He T
        • Jin S
        • et al.
        A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
        Chin J Cancer Res. 2022; 34: 53-62
        • Adkins S
        CAR T-cell therapy: adverse events and management.
        J Adv Pract Oncol. 2019; 10: 21-28
        • Strati P
        • Varma A
        • Adkins S
        • et al.
        Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
        Haematologica. 2021; 106: 2667-2672
        • Gudiol C
        • Lewis RE
        • Strati P
        • Kontoyiannis DP
        Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?.
        Lancet Haematology. 2021; 8: e216-e228
        • Rejeski K
        • Perez Perez A
        • Sesques P
        • et al.
        CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
        Blood. 2021; 138: 2499-2513